pSivida CEO to participate at glaucoma conference

pSivida (NASDAQ:PSDV; ASX:PVA) CEO Dr. Paul Ashton will participate today in a panel: New Horizons in Glaucoma Drug Delivery and IOP Monitoring during the Glaucoma 360 New Horizons forum at the Palace Hotel in San Francisco. The conference is being presented by the Glaucoma Research Foundation in association with Ophthalmology Times to bring together leaders [...]

pSivida takes us on a fantastic voyage to the back of the eye

After developing several miniaturized, injectable drug delivery systems for the treatment of niche ocular diseases, pSivida (NASDAQ:PSDV; ASX:PVA) is now at the precipice of several blockbuster indications, including diabetic macular edema (DME), age-related macular degeneration (AMD) and glaucoma, with its next-generation Durasert device. And in early development is a new generation Tethadur platform that relies [...]

eSight eyes commercial launch this fall

Closely held eSight is set to begin the final stages of patient evaluation of its intelligent eyewear, setting the stage for a commercial launch in the fall. “We think this will make a big difference in the quality of people’s lives,” CEO Kevin Rankin says in an exclusive interview with BioTuesdays.com. “Our device will enable [...]